001     281113
005     20250924102922.0
024 7 _ |a 10.1212/WNL.0000000000213677
|2 doi
024 7 _ |a pmid:40906975
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
037 _ _ |a DZNE-2025-01074
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kancheva, Ivana Kirilova
|0 0000-0002-1151-6243
|b 0
245 _ _ |a Cerebrovascular Reactivity at Rest and Its Association With Cognitive Function in People With Genetic Frontotemporal Dementia.
260 _ _ |a Philadelphia, Pa.
|c 2025
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758628993_10852
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebrovascular reactivity (CVR) is an indicator of cerebrovascular health, and its signature in familial frontotemporal dementia (FTD) remains unknown. The primary aim was to investigate CVR in genetic FTD using an fMRI index of vascular contractility termed resting-state fluctuation amplitudes (RSFAs) and to assess whether RSFA differences are moderated by age. A secondary aim was to study the relationship between RSFA and cognition.Participants included presymptomatic and symptomatic C9orf72, GRN, and MAPT pathogenic variation carriers, along with noncarriers, from the prospective Genetic FTD Initiative cohort study. Cross-sectional differences in CVR were assessed using both component-based and voxel-level RSFA maps. To study disease progression-related effects, the moderating effect of age on differences between genetic status groups was analyzed using generalized linear models. The influence of RSFA, and its interaction with genetic status, on participants' cognitive function was also examined. All models were adjusted for sex, handedness, and scanning site and false discovery rate-corrected at p < 0.05.A total of 284 presymptomatic and 124 symptomatic sequence variation carriers, and 265 noncarriers, were included in the analysis (mean age 48.17 years, 55% female). Across the sample, symptomatic carriers exhibited lower RSFA and a greater age-related RSFA decline predominantly in the medial frontal (-0.07 standard units, p = 0.046, 95% CI -0.13 to -0.01) and posterior parietal (-0.06 standard units, p = 0.048, 95% CI -0.12 to 0.01) cortex, compared with presymptomatic carriers and noncarriers. RSFA was inversely correlated with age (-0.43 standard units, p < 0.001, 95% CI -0.48 to -0.37) and positively associated with cognitive function (0.09 standard units, p = 0.008, 95% CI 0.04-0.15), particularly in the prefrontal cortex, in sequence variation carriers across the sample, independent of disease stage.CVR impairment in genetic FTD has a predilection for the middle frontal and posterior cortex, and its preservation may yield a cognitive benefit for at-risk individuals. Although findings do not provide causality and warrant replication, they support the notion that vascular dysfunction in familial FTD may be a target for biomarker identification and disease-modifying efforts.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a C9orf72 Protein
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a MAPT protein, human
|2 NLM Chemicals
650 _ 7 |a C9orf72 protein, human
|2 NLM Chemicals
650 _ 7 |a Progranulins
|2 NLM Chemicals
650 _ 7 |a GRN protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: physiopathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: diagnostic imaging
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: psychology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Cognition: physiology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a tau Proteins: genetics
|2 MeSH
650 _ 2 |a Cerebrovascular Circulation: physiology
|2 MeSH
650 _ 2 |a Progranulins: genetics
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: physiopathology
|2 MeSH
650 _ 2 |a Brain: blood supply
|2 MeSH
650 _ 2 |a Rest
|2 MeSH
700 1 _ |a Bouzigues, Arabella
|0 0000-0002-0267-8590
|b 1
700 1 _ |a Russell, Lucy Louise
|0 0000-0001-5023-5893
|b 2
700 1 _ |a Foster, Phoebe H
|0 0000-0001-6300-6598
|b 3
700 1 _ |a Ferry-Bolder, Eve
|0 0009-0006-5083-0901
|b 4
700 1 _ |a Van Swieten, John C
|b 5
700 1 _ |a Jiskoot, Lize Corrine
|0 0000-0002-1120-1858
|b 6
700 1 _ |a Seelaar, Harro
|0 0000-0003-1989-7527
|b 7
700 1 _ |a Sánchez-Valle, Raquel
|0 0000-0001-7750-896X
|b 8
700 1 _ |a Laforce, Robert
|0 0000-0002-2031-490X
|b 9
700 1 _ |a Graff, Caroline
|0 0000-0002-9949-2951
|b 10
700 1 _ |a Galimberti, Daniela
|0 0000-0002-9284-5953
|b 11
700 1 _ |a Vandenberghe, Rik
|0 0000-0001-6237-2502
|b 12
700 1 _ |a de Mendonça, Alexandre
|0 0000-0002-0488-1453
|b 13
700 1 _ |a Tiraboschi, Pietro
|0 0000-0002-2171-1720
|b 14
700 1 _ |a Santana, Isabel
|0 0000-0002-8114-9434
|b 15
700 1 _ |a Gerhard, Alexander
|0 0000-0002-8071-6062
|b 16
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 17
700 1 _ |a Sorbi, Sandro
|0 0000-0002-0380-6670
|b 18
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 19
700 1 _ |a Ducharme, Simon
|0 0000-0002-7309-1113
|b 20
700 1 _ |a Butler, Christopher
|0 0000-0002-7502-9284
|b 21
700 1 _ |a Le Ber, Isabelle
|0 0000-0002-2508-5181
|b 22
700 1 _ |a Finger, Elizabeth
|0 0000-0003-4461-7427
|b 23
700 1 _ |a Tartaglia, Maria Carmela
|0 0000-0002-5944-8497
|b 24
700 1 _ |a Masellis, Mario
|0 0000-0002-6244-2096
|b 25
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 26
700 1 _ |a Moreno, Fermin
|0 0000-0001-5200-3164
|b 27
700 1 _ |a Borroni, Barbara
|0 0000-0001-9340-9814
|b 28
700 1 _ |a Rohrer, Jonathan Daniel
|0 0000-0002-6155-8417
|b 29
700 1 _ |a van der Weerd, Louise
|b 30
700 1 _ |a Rowe, James B
|0 0000-0001-7216-8679
|b 31
700 1 _ |a Tsvetanov, Kamen
|0 0000-0002-3178-6363
|b 32
700 1 _ |a Consortium, GENFI
|b 33
|e Collaboration Author
773 _ _ |a 10.1212/WNL.0000000000213677
|g Vol. 105, no. 6, p. e213677
|0 PERI:(DE-600)1491874-2
|n 6
|p e213677
|t Neurology
|v 105
|y 2025
|x 0028-3878
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281113/files/DZNE-2025-01074.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281113/files/DZNE-2025-01074.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281113
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21